School Of Health Sciences

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/102

Browse

Has files: NoSubject: search.filters.subject.biomarker

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cancer informatics analysis indicates high CHAC2 associated with unfavorable prognosis in breast cancer
    (Frontiers Media S.A., 2022-12-09T00:00:00) Chand, Subhash; Mehta, Vikrant; Sharma, Ratnesh K.; Anvikar, Anupkumar R.; Chander, Harish
    Breast cancer remains the most commonly diagnosed cancer worldwide and exhibits a poor prognosis. The induction of genetic changes deregulates several genes that increase the disposal towards this life-threatening disease. CHAC2, a member of the glutathione degrading enzyme family has been shown to suppress gastric and colorectal cancer progression, however, the expression of CHAC2 in breast cancer has not been reported. We did an analysis of CHAC2 expression in breast cancer patients from various online tools like UALCAN, GEPIA2, GENT2, TIMER2, and bcGenExminer v4.8. Further, we used the Kaplan-Meier plotter to establish the significance of CHAC2 in BC patient survival and prognosis while TISIDB and TIMER databases were used to investigate the filtration of immune cells. The results showed that CHAC2 levels were high in breast cancer patients and elevated CHAC2 was associated with low overall survival. Taken together, the results of the present study show that like its paralog CHAC1, CHAC2 may also be an important biomarker and could have a potential therapeutic implication in breast cancer. Copyright � 2022 Chand, Mehta, Sharma, Anvikar and Chander.
  • No Thumbnail Available
    Item
    miRNA dysregulation in ischaemic stroke: Focus on diagnosis, prognosis, therapeutic and protective biomarkers
    (Blackwell Publishing Ltd, 2020) Vasudeva, K; Munshi, A.
    Stroke is one of the leading causes of death and disability in both developing and developed countries. Biomarkers for stroke and its outcome can greatly facilitate early detection and management of the disease. miRNAs have been explored for their potential as biomarkers for diagnosis, prognosis and brain injury in ischaemic stroke. A substantial body of evidence suggests that miRNAs play key roles in numerous cellular changes following ischaemic stroke including mitochondrial dysfunction, energy failure, cytokine-mediated cytotoxicity, oxidative stress, activation of glial cells, increased intracellular calcium levels inflammatory responses and disruption of the blood�brain barrier (BBB). In addition, targeting specific miRNAs, therapeutic modulation of brain injury and apoptosis can also be achieved. Therefore, the current review has been compiled within an aim to give an overview of the developments exploiting miRNAs at different stages of stroke as prognostic, diagnostic, protective and therapeutic biomarkers. � 2020 Federation of European Neuroscience Societies and John Wiley & Sons Ltd